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The most recent new emerging infection is the H5N6 inﬂuenza virus infection. This
infection has just been reported from China in early May 2014. The disease is believed to
be a cross species infection. All indexed cases are from China. Of interest, the H5N6
inﬂuenza virus is the primary virus for avian. The avian H5N6 inﬂuenza virus in avian
population is a low virulent strain. However, the clinical manifestation in human seems
severe. In this mini-review, the authors summarize and discuss on this new emerging
inﬂuenza.1. Introduction
Inﬂuenza is an important virus. This virus can cause the
infection in both human beings and animals. It is considered as an
important virus. Medically, this infection can be seen in any
countries around the world. The classical inﬂuenza infection can
cause respiratory illness and becomes an important consideration
in medicine. However, for a long time, the emerging of new
inﬂuenza can be problematic. In medical history, the best example
is the Spanish ﬂu [1], which is a previous emerging inﬂuenza that
killed millions of population. Hence, the emerging inﬂuenza
becomes the important situation to be discussed in medicine [2].
Within the past few years, there are several new emerging
inﬂuenzas. Those emerging inﬂuenza infections include H5N1
bird ﬂu [3], H1N1 swine ﬂu [4], H7N9 inﬂuenza [5] and H5N2
inﬂuenza [6]. Webster et al. recently said that “continuing
challenges in inﬂuenza include the emergence of pandemic
H1N1 inﬂuenza in 2009, human infections with avian H7N9
inﬂuenza in 2013, and sporadic human cases of highly
pathogenic avian H5N1 inﬂuenza [7].” However, there are not
only those mentioned new emerging inﬂuenza infections, but
also other continuous new emerging inﬂuenza infections.
The most recent new emerging infection is the H5N6 inﬂu-
enza virus infection [8]. This infection has just been reportedfrom China in early May 2014. The disease is believed to be a
cross-species infection. The ﬁrst indexed case is an old male
patient presenting with acute respiratory illness, pneumonia, and
ended up with death. Of interest, the H5N6 inﬂuenza virus is the
primary virus for avian. There is also an available avian vaccine
for this virus [9]. An interesting opinion is that the avian H5N6
inﬂuenza virus is a low virulent strain. It does not cause severe
disease in the avian population. However, the clinical
manifestation in human seems severe. In this mini-review, the
authors summarize and discuss on this new emerging inﬂuenza.
2. Emerging of human H5N6 inﬂuenza in 2014: a
new problem
As already noted, the H5N6 inﬂuenza is considered a new
emerging infection. This viral disease is caused by inﬂuenza
virus. It is considered as a new atypical viral infection and a
member of new emerging bird ﬂu with medical importance. Any
new bird ﬂu might cause serious disease that is hard for control
and management. Since the ﬁrst emerging of bird ﬂu H5N1 in
human beings, there are many following bird ﬂu that lead to
worldwide concern. The great concern is on its possible
pandemic, which can be a serious event (as the case of Spanish
ﬂu in medical history). For sure there is also a great concern for
the newest emerging H5N6 inﬂuenza infection.
The H5N6 inﬂuenza virus infection is mainly conﬁned
among avian population. However, the cross-species infection to
human beings becomes a new episode of the new emerginger the CC BY-NC-ND
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has attracted a lot of attention of medical society. WHO docu-
ments that the emerging inﬂuenza infection is becoming an
actual threaten to global public health system and recommends
that the international collaboration to manage this problem is
required [10]. For the new emerging avian inﬂuenza infection,
Anderson et al. concluded that the main aims towards
management include “(1) identify virological characteristics of
avian inﬂuenza viruses (AIVs) important for zoonotic and
pandemic disease, (2) evaluate the factors affecting evolution
and emergence of a pandemic inﬂuenza strain and identify
existing monitoring systems, and (3) identify modes of
transmission and exposure sources for human zoonotic
inﬂuenza infection (including discussion of speciﬁc exposure
risks by affected countries) [11].”
To reach the success in management of the new inﬂuenza,
there are several requirements. Duaphin et al. mentioned the
important things in coping with new emerging inﬂuenza which
include “commercial diagnostic kit evaluation, applied epide-
miology, biosafety, vaccination, proﬁciency testing, develop-
ment of standardized reference materials for sera and RNA, and
issues at the human–animal interface [12]”. For the new
emerging H5N6 inﬂuenza infection, it is no doubt that those
mentioned requirements have to be fulﬁlled and should be the
priorities for the present focus. Morikane noted that “there is
still much uncertainty” regarding the emerging inﬂuenza and
noted that the “ﬂexibility of the policy in response to its
nature might have saved us from an initial catastrophe in
affected regions, and should be well-reﬂected for the prepara-
tion of the next, unforeseeable pandemic of emerging infectious
disease [13].”
3. Genetic alteration in the new H5N6 inﬂuenza
infection
An important consideration on any new emerging inﬂuenza
infection is its origin. “Why the new virus occurs?” is a basic
query to be answered. In fact, any virus has the genetic
component. A classical virus might have a speciﬁc genetic
component. This is also a basic concept when a scientist talks
about the inﬂuenza virus. However, as a virus, its rapid repli-
cation means many multiplication cycles comparing to that of
other living things. With many cycles, the chance of error in
process during cycle can be expected. This can be simply
explained by probability in mathematical statistical theory [14].
This is a real fact for the emerging avian inﬂuenza infection.
Trampuz et al. concluded that “the widespread epidemic of
avian inﬂuenza in domestic birds increases the likelihood for
mutational events and genetic reassortment [15]” and “the
threat of a future pandemic from avian inﬂuenza is real [15].”
It is apparently proposed that genetic alteration is the basic
problem causing existence of the new inﬂuenza virus. Reid
and Taubenberger concluded that “novel inﬂuenza virus strains
emerge periodically to which humans have little immunity,
resulting in devastating pandemics [16].”
Generally, the genetic alteration which is called genetic
reassortment is the basic ﬁndings in any new emerging inﬂuenza
virus infections [17]. The observation is well described in the
case of H5N1 bird ﬂu [18–20] and H1N1 swine ﬂu [21–23]. The
pathogenic H5N6 inﬂuenza virus is proved to be a new
emerging inﬂuenza virus. There are some recent reports on the
genetic alteration of the new H5N6 inﬂuenza virus. Bi et al.recently reported the problem within the genetic component of
the new emerging H5N6 inﬂuenza virus [8]. Bi et al. reported
that “genetic and phylogenetic analyses revealed that these
H5N6 viruses are novel reassortants between H5N1 clade
2.3.4 and H6N6 viruses, and have evolved into two distinct
lineages (Sichuan and Jiangxi) [8]”. Bi et al. found that “H5N6
viruses contained a T160A substitution in the HA protein and
an 11-amino acid-deletion in the neuraminidase (NA) stalk,
which may aid in enhancing viral afﬁnity for human-like re-
ceptors, and virulence in mammals [8].” The genetic clariﬁcation
of the new emerging H5N6 inﬂuenza virus is very important for
further research and development on this new infection.
Indeed, the genetic reassortment that leads to the new virus
has previously been observed [24,25]. As noted by Qi et al.,
“phylogenetic analysis showed that the isolate was a novel
reassortant virus with a neuraminidase gene from H6N6
viruses and the other seven genes from H5N1 viruses, which
may pose a potential threat to human and animal health [25].”
However, there has never been human case. A good example
was reported by Ma et al. [24]. The observation was on the
H10N6 variant [24]. Ma et al. noted that “H10 viruses further
reassorted, apparently with H5N6 viruses, and generated an
H10N6 variant [24].”
4. Clinical presentation of the new H5N6 inﬂuenza
infection
Clinical presentation of the new H5N6 inﬂuenza infection is
very interesting. As an inﬂuenza virus infection, the classical
signs and symptoms of the classical inﬂuenza are expected to be
detectable in new H5N6 inﬂuenza infection. The classical clin-
ical feature of the classical inﬂuenza is an acute febrile illness
with respiratory signs and symptoms. However, H5N6 inﬂuenza
infection is a new atypical bird ﬂu, the typical clinical signs and
symptoms can be expected. Generally, a new atypical inﬂuenza
infection usually manifests non respiratory signs and symptoms
such as gastrointestinal and neurological manifestations [26,27].
For the new emerging H5N6 inﬂuenza virus infection, there
are few information on the clinical presentation since there are
only 2 recorded human cases at present (all cases are adults).
The ﬁrst case of H5N6 inﬂuenza virus infection presented with
severe clinical features. Severe pneumonia was observed in this
case and the patient ended up with death. Focusing on the sec-
ond case, which is also recorded from China, similar clinical
features and clinical course could be observed. Both cases have
signs and symptoms of severe respiratory tract illness. A rapid
progression of illness to pneumonia can be seen and this is
considered the reﬂection of severity of the infection. The atyp-
ical non respiratory illness is not signiﬁcantly noted in these two
cases. The common risk factor as exposure to death poultry
could be identiﬁed in the indexed cases. According to the sug-
gestion by local Chinese Centers for Disease Control (CDC), it
is concluded that “both the ﬁrst and second human H5N6 in-
fections are sporadic cases. Thus far, there is no evidence of
sustained human-to-human transmission of the virus. Travelers
visiting China are urged to practice good personal hygiene and
avoid contact with poultry and birds to ward off infection [28].”
The local CDC also suggested for preventive measures including
“avoiding visiting live poultry market and live bird market,
avoiding direct contact with poultry and birds or their
droppings, consuming only thoroughly cooked poultry and
eggs, and washing hands frequently [28].”
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The epidemiology of the emerging H5N6 inﬂuenza infection
is presently widely studied. The infection can be seen in avian
population worldwide. Nevertheless, the information on human
infection in the new emerging episode is a focused point for
medical community. In fact, the information on new emerging
human H5N6 inﬂuenza infection is limited. The two indexed
cases of new emerging H5N6 inﬂuenza infection occurred in
China but in different provinces (Sichuan Province and
Guangdong Province). Both cases are adult (49 years old and 58
years old). As already noted, both cases have the history of
contact to dead poultry before getting infection. Qi et al. noted
that “live poultry markets may play an important role in the
evolution and transmission of avian inﬂuenza viruses [25].”
Indeed, at present, the existence of circulating H5N6 inﬂuenza
virus can be seen in many areas of China [28]. For the possible
human-to-human transmission, the investigation on the closely
related persons to both patients showed no evidence of infection
[28]. Nevertheless, information from only two indexed cases are
extremely few for reaching the conclusion on the epidemiology
of the new emerging infection. Qi et al. concluded that “the
epidemiology and biological characterization of the H5N6
virus are still unknown in China [25].”
6. Clinical diagnosis of the new H5N6 inﬂuenza
infection
The clinical diagnosis of the new H5N6 inﬂuenza infection is
a big challenge. Indeed, the diagnosis of the new emerging
inﬂuenza infection is not easy. The disease cannot be diagnosed
by clinical presumptive diagnosis. The clinical ﬁndings are
usually not differentiable from other acute respiratory illness and
this makes the difﬁculty to reach the deﬁnitive diagnosis. In both
indexed cases, the ﬁnal diagnoses can be derived after the mo-
lecular diagnosis of the genetic components of the isolated vi-
ruses [28]. PCR is usually the tool for deﬁnitive diagnosis.
Focusing on the speciﬁc observation from genetic study, Qi
et al. reported that the new virus has “the full lengths of the
polymerase PB2 and PB1, polymerase acidic protein (PA),
hemagglutinin (HA), nucleoprotein (NP), neuraminidase (NA),
matrix (M), and nonstructural (NS) genes were 2,341, 2,341,
2,233, 1,776, 1,565, 1,464, 1,027, and 890 nucleotides,
respectively [25]” and “the amino acid sequence of the
cleavage site in the HA protein was PLREKRRKRYGLF [25]”
which conﬁrmed the nature of the highly pathogenic bird ﬂu [29].
However, an important consideration on the diagnosis is the
availability of the diagnostic tool and consideration of the
practitioner to recognize the possibility of occurrence of the new
infection. The local CDC suggested that the investigation should
be considered in any cases with unexplained acute febrile illness
with severe respiratory manifestation and have history of contact
to dead poultry or travel to the risk area [28].
7. How to treat the patient with new H5N6 inﬂuenza
infection
As a new emerging infectious disease, it is difﬁcult to
manage the infected cases. Since there is no knowledge, the
treatment is usually a new trial. However, as a member of
inﬂuenza, the management of the case can be based on thegeneral treatment of inﬂuenza. The antiviral drug for the inﬂu-
enza virus infection is presently available [30]. Also, the
management of the inﬂuenza should also include the
symptomatic and supportive management. This is the basic
requirement in clinical management of inﬂuenza.
The widely used antiviral at present is oseltamivir [31]. In
fact, oseltamivir is the antiviral drug for management of
classical inﬂuenza infection. It was also used for management
of the patients with the new atypical inﬂuenza infection [32].
However, the common problem is the unknown effectiveness
of the drug. For sure, the information is usually lack and it is
usually problematic in the ﬁrst phase of disease outbreak [32].
Based on the data on the available two indexed cases, it was
not proved that the use of oseltamivir can be effective against
the new emerging H5N6 inﬂuenza infection. Nevertheless, the
use of oseltamivir in avian infection is still proved to be
effective and there is no problem of drug resistance [33].
8. Prevention for the new H5N6 inﬂuenza infection
Vaccine is usually a hope for disease control and prevention.
As a new emerging infection, there is no speciﬁc vaccine for it.
However, it should be noted that the vaccine is available for
animal. The “adjuvanted heterologous H5N6 avian inﬂuenza vi-
rus vaccine” is available and can be used for disease prevention in
animal [9]. This vaccine was studied in feline model and also
found to be effective for prevention against H5N1 bird ﬂu [9].
Nevertheless, there is still no trial of the mentioned vaccine on
human beings. It is urgently needed to ﬁnd the new vaccine to
correspond to the possible pandemic of H5N6 inﬂuenza. The
use of bioinformatics might be helpful for ﬁnding the new
vaccine. The ongoing researches on this speciﬁc area can be
seen in several modern medical research laboratories [32].
Apart from the use of vaccine, the basic prevention measures
towards H5N6 inﬂuenza infection should not be forgotten. Basic
sanitation seems to be important for prevention of any new
emerging inﬂuenza infections [34]. This should include the
promotion of hand washing and use of face mask. However,
the success of the prevention depends on good plan and
management. To manage the new emerging infection, Coker
et al. proposed that “the challenges in control of emerging
infectious diseases are formidable and range from inﬂuencing
the factors that drive disease emergence, to making
surveillance systems ﬁt for purpose, and ensuring that regional
governance mechanisms work effectively to improve control
interventions [34].”
9. Future perspective
More researches and studies on this newest emerging inﬂu-
enza infection are necessary. Until present (January 2015), it
seems that there are too few data on this speciﬁc infection. A
possible explanation might be due to the little extension of this
disease from its origin. Nevertheless, there is an interesting sci-
entiﬁc report from China on the genetics of the H5N6 inﬂuenza.
Qi et al. reported on “whole-genome sequence of a reassortant
H5N6 avian inﬂuenza virus isolated from a live poultry market in
China [25].” Based on this information, it is no doubt that the new
H5N6 inﬂuenza can be a possible problematic infection and the
consideration from the medical society around the world is
needed. Finally, due to the conﬁned foci of the infection, the
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new infection might be little progressed. It should be noted that
there is an inactivated, adjuvanted heterologous H5N6 avian
inﬂuenza virus vaccine which is available for animal [9] but it
is not approved for human beings at all. In the next 5 year, it
is expected that there will be more cases of the new H5N6
inﬂuenza infection and there will also be many new researches
and development on diagnostic tool, antiviral drug and vaccine
towards this new disease.
10. Conclusion
The emerging of the new H5N6 inﬂuenza infection from
China leads to several concerns in the medical community. As a
new emerging infection, Urgent knowledge collection on the
new H5N6 inﬂuenza infection is recommended. Several con-
cerns for the present situation of emerging H5N6 inﬂuenza in
human beings are as followings: (1) It is required to tract the
tract of cross-species infection of this new infection. The tools
can be genomics, epidemiology and clinical studies. (2) The
promotion of health sanitation to prevent spreading of the dis-
ease is needed. The basic rule for prevention of respiratory
contagious disease can be applied. (3) Surveillance system to
identity any new emerging disease is needed. In the mean time,
it is required to provide wide scale health education to both
medical personnel and general practitioner to cope with this
newest infection. (4) Also, ﬁnding for a new drug and vaccine to
correspond to the new infection must be parallel done. (5)
Finally, it calls for international participation and sharing of
knowledge towards this new disease.
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